Umbilical Stem Cells: Potential 'Holy Grail' for Regenerative Medicine
New review highlights Wharton's Jelly stem cells as a promising, non-invasive option for regenerative therapies.
Why it matters
- Offers a non-invasive, scalable source of stem cells for various conditions.
By the numbers
- Journal impact factor: 7.5
- ALS study reported a 31% decrease in progression rate for some patients
The big picture
- WJ-MSCs show potential in orthopedics, autoimmune conditions, neurodegenerative diseases, and tissue engineering
What they're saying
- Expert skepticism on past MSC trials; some personal anecdotes highlight hope
Caveats
- Review synthesizes existing research; mixed clinical trial results
- Risks of unregulated use
What’s next
- Ongoing trials and potential FDA approvals pending efficacy proof